## Diagnosis: Plasmodium vivax Malaria (Uncomplicated) ### Diagnostic Features **Key Point:** Schüffner's stippling on blood smear is pathognomonic for *Plasmodium vivax* (and P. ovale). The tertian fever pattern (fever every 48 hours) is classic for P. vivax due to the 48-hour erythrocytic cycle. **Clinical Pearl:** The maculopapular rash on day 5 is a recognized feature of P. vivax malaria and does NOT indicate severe malaria—it is part of the natural history of uncomplicated vivax malaria. Rash in malaria is typically seen during the defervescence phase and is benign. **High-Yield:** P. vivax and P. ovale form hypnozoites (dormant liver forms) that can reactivate weeks to months later, causing relapse. This necessitates primaquine for radical cure. ### Severity Assessment | Criterion | Present | Interpretation | |-----------|---------|----------------| | Parasitemia level | Not stated | Likely <1% (uncomplicated) | | Organ dysfunction | None | No renal/hepatic/cerebral involvement | | Severe anemia | Not mentioned | Presumed absent | | Rash | Yes | Benign feature of vivax malaria | | Hemodynamic stability | Implied | Afebrile period suggests stable | **Warning:** Do NOT confuse rash in malaria with severe malaria. The rash in P. vivax is typically maculopapular, appears during defervescence, and is self-limited. It does NOT mandate parenteral therapy. ### Treatment Algorithm for P. vivax ```mermaid flowchart TD A[P. vivax malaria confirmed]:::outcome --> B{Severe features?}:::decision B -->|No| C[Uncomplicated vivax malaria]:::outcome B -->|Yes| D[Severe vivax malaria - rare]:::urgent C --> E[Chloroquine 600 mg base stat]:::action E --> F[300 mg at 6, 24, 48 hours]:::action F --> G[Fever clearance in 48-72 hours]:::outcome G --> H[Primaquine 0.5 mg/kg/day for 14 days]:::action H --> I[Eradicate hypnozoites - prevent relapse]:::outcome D --> J[IV Artesunate then switch to oral ACT]:::action ``` ### Chloroquine Dosing for P. vivax **Key Point:** Chloroquine remains the drug of choice for uncomplicated P. vivax malaria because P. vivax has NOT developed widespread chloroquine resistance (unlike P. falciparum). - **Loading dose:** 600 mg base (= 1000 mg salt) immediately - **Maintenance:** 300 mg base at 6, 24, and 48 hours - **Total dose:** 1500 mg base over 3 days - **Fever clearance:** Expected within 48–72 hours ### Primaquine for Radical Cure **High-Yield:** Primaquine is MANDATORY for P. vivax and P. ovale to prevent relapse (reactivation of hypnozoites). - **Dose:** 0.5 mg/kg/day for 14 days (standard) or 0.75 mg/kg/day for 8 days (alternative) - **Timing:** Start after acute symptoms resolve and hemoglobin recovers (typically after day 3–5 of chloroquine) - **G6PD screening:** Essential before primaquine (risk of hemolysis in G6PD-deficient patients) **Clinical Pearl:** Primaquine should NOT be given during the acute febrile phase or in severely ill patients. It is safe to give during the afebrile period once the patient is clinically improving. ### Why Other Options Are Incorrect **Quinine (Option C):** Quinine is reserved for severe malaria or chloroquine-resistant P. vivax (rare). It is inferior to chloroquine for uncomplicated vivax malaria and requires IV administration. **Mefloquine (Option D):** Mefloquine is a second-line agent for uncomplicated malaria but is less effective than chloroquine for P. vivax. It does not eliminate hypnozoites and must be combined with primaquine. The dosing regimen given is also suboptimal. **Artesunate (Option B):** Artesunate is reserved for severe malaria. This patient has uncomplicated vivax malaria with a benign rash—parenteral therapy is not indicated. [cite:Harrison 21e Ch 217; KD Tripathi 8e Ch 66]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.